Glaukos Corporation
Aliso Viejo, CA
- UEI
- M77LMBPAZLL9
- CAGE
- 8QAP5
- Primary NAICS
- 339115 Ophthalmic Goods Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- Corporate family
-
-
- XVMEKBSUMGZ7
-
- SAM.gov registration date
- Physical address
- 1 Glaukos Wy, Aliso Viejo, CA 92656, USA
- Website
- glaukos.com
- Founded
- 1998
- Employees
- 251-1K
- Estimated annual revenue
- $100M-$250M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Equipment & Supplies
- Eyewear
- SIC code
- 59 Miscellaneous Retail
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | -$21,311 |
| FY2025 | $128,043 |
| FY2024 | $31,966 |
Contract vehicles
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Avedro, Inc. | — | 339112 Surgical and Medical Instrument Manufacturing |
| BCC Financial Services | Irvine, CA | 339113 Surgical Appliance and Supplies Manufacturing |
| Melling Medical | Alexandria, VA | 339112 Surgical and Medical Instrument Manufacturing |
| Oculus Surgical Inc. | Port St. Lucie, FL | 339112 Surgical and Medical Instrument Manufacturing |
| Or Elder Inc. | New York, NY | 423460 Ophthalmic Goods Merchant Wholesalers |
About the company
Glaukos Corporation, a for-profit medical device manufacturer based in Aliso Viejo, California, supplies ophthalmic surgical implants and pharmaceutical products to the Department of Veterans Affairs as a full-and-open prime contractor across multiple Veterans Integrated Service Networks. The company holds no SBA set-aside certifications and competes on unrestricted basis. Glaukos owns a named subsidiary, Avedro, Inc., which operates as a co-awardee on several VA Federal Supply Schedule contracts and delivers orders through the same Pharmaceuticals and Drugs (FSS-61-IB) schedule.
Glaukos's federal footprint concentrates entirely on the VA healthcare system across four regional VISNs. The company has completed thirteen prime awards totaling $872 thousand in combined potential value since June 2023, with thirteen outstanding awards placing all work through VA networks. VISN 12 anchors the potential-value ranking ($584 thousand on a single Federal Supply Schedule contract), while VISN 23 leads by award count with six purchase orders ($128 thousand combined potential value). VISN 15 holds five awards ($149 thousand combined potential value), and VISN 19 one award ($11 thousand). All thirteen awards are full-and-open, firm-fixed-price contracts with no set-aside designations.
Glaukos's capability portfolio centers on IDOSE TRAVOPROST implants for glaucoma treatment, surgical prosthetics (prosthetic implants for the right and left eye), and related ophthalmic medical devices. Representative work includes a June 1, 2023, Federal Supply Schedule award from GSA under Pharmaceuticals and Drugs (FSS-61-IB) with a $584 thousand ceiling running through May 31, 2028, covering drugs, pharmaceuticals, and hematology-related products for VA procurement; a February 1, 2025, blanket purchase agreement with VISN 15 for IDOSE TRAVOPROST 75MCG IMPLANT valued at $106,553 with performance through January 31, 2030; and multiple individual purchase orders from VISN 23 for surgical implants ranging from $21,341 each (May–June 2025). Recent subsidiary activity through Avedro includes a February 1, 2026, BPA call from VISN 15 for $21,311 in IDOSE TRAVOPROST 75MCG IMPLANT and delivery orders from VISN 12, VISN 5, and other networks totaling $489 thousand across 2024–2026.
Activity has grown from one award in 2023 to eight in 2025, though most work falls into purchase-order and BPA-call structures with modest per-transaction values ($10–$21 thousand individually). One award ($21 thousand) completes in the next twenty-four months, representing minimal recompete exposure in that window. The company's obligation rate stands at 21% of potential value, reflecting the typical lag between contract ceiling and invoiced spend on medical-device supply contracts. Glaukos competes solely through the Pharmaceuticals and Drugs schedule; no other parent vehicles appear in the award record.
Quick answers
Is Glaukos Corporation registered in SAM.gov?
Yes. Glaukos Corporation's SAM.gov registration is active through March 11, 2027.
Which contract vehicles does Glaukos Corporation hold?
Glaukos Corporation holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Glaukos Corporation received in federal contracts?
Federal contracts obligated $128,043 to Glaukos Corporation in fiscal year 2025 and $138,699 in fiscal years 2023 through 2027.
What is Glaukos Corporation's most recent federal award?
Glaukos Corporation's most recent federal contract award is Idose travoprost 75MCG implant (36C25526N0092), from Veterans Integrated Service Network 15 (VHA), on February 1, 2026.
On GovTribe
See Glaukos Corporation's full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors